Scope, Claims, and Patent Landscape Analysis of U.S. Patent 4,994,278
Summary
U.S. Patent 4,994,278, granted on February 19, 1991, to Schering Corporation (later acquired by Merck & Co.), covers a novel class of synthetic compounds with significant pharmaceutical potential. The patent primarily claims a series of non-peptide selective dopamine receptor antagonists, with potential applications in psychotic disorders, schizophrenia, and other neuropsychiatric conditions.
This detailed analysis elucidates the scope and claims of the patent, contextualizes its position within the broader patent landscape regarding dopamine receptor antagonists, and assesses its relevance for current and future pharmaceutical development. It explores the patent's claims boundaries, innovative features, and influence on subsequent patent filings and research trajectories.
1. Patent Overview and Context
1.1 Basic Details
| Attribute |
Details |
| Patent Number |
4,994,278 |
| Filing Date |
December 20, 1989 |
| Issue Date |
February 19, 1991 |
| Assignee |
Schering Corporation (now part of Merck & Co.) |
| Patent Expiry |
December 20, 2006 (assuming no extensions) |
| Priority Filing Date |
December 20, 1988 (priority application) |
1.2 Background & Innovation
The patent discloses a new class of 3,4-dihydro-2H-1-benzazepines, which act as selective dopamine D2 receptor antagonists. These compounds are positioned as therapeutics for neuropsychiatric and psychotic disorders, offering improved selectivity, potency, and reduced side effects relative to earlier compounds.
1.3 Technological Significance
Prior art before 1991 included typical antipsychotics (e.g., chlorpromazine) with non-specific receptor binding, leading to significant adverse effects. The patent's focus on selective D2 antagonists represented a strategic advance, aiming for antipsychotic efficacy with fewer extrapyramidal side effects.
2. Scope of the Patent: Main Objectives
2.1 Types of Compounds Covered
The patent claims a broad class of compounds characterized by their structural core:
- Chemical Class: 3,4-dihydro-2H-1-benzazepines.
- Substitutions: R1, R2, R3, and other groups on the core, with claimed variations encompassing alkyl, aryl, and heteroaryl groups.
2.2 Biological Activity
The compounds are claimed to:
- Exhibit selective binding to dopamine D2 receptors.
- Demonstrate antipsychotic activity.
- Possess favorable side effect profiles relative to non-selective agents.
2.3 Pharmacological Claims
- Binding affinity for dopamine D2 receptors with specific Ki values (< 100 nM).
- Selectivity over D1, D3, and other receptor subtypes.
- Utility as medicinal agents, primarily for schizophrenia, psychosis, and related disorders.
3. Claim Analysis
3.1 Independent Claims Overview
The critical independent claim (Claim 1) broadly encompasses:
"A compound of the formula I: [structural formula], wherein R1, R2, R3, and X are as defined, and the compound exhibits affinity for dopamine D2 receptors."
Key features include:
- Structural variability within defined chemical groups.
- The pharmacological activity as a dopamine D2 receptor antagonist.
3.2 Claim Elements Breakdown
| Claim Element |
Description |
Limitations |
| Structural core |
3,4-dihydro-2H-1-benzazepine |
Must follow core scaffold, but with substitution flexibility |
| Substituents R1, R2, R3 |
Alkyl, aryl, heteroaryl groups, with specific size or electronic constraints |
Variability within defined chemical space |
| Receptor affinity |
Binding affinity (Ki) < 100 nM for D2 receptors |
Biological activity requirement |
| Pharmacological utility |
Use as pharmaceuticals for neuropsychiatric disorder treatment |
Therapeutic application specified |
3.3 Dependent Claims
Dependent claims specify particular substituents, pharmaceutical compositions, preferred compounds, and methods of use.
For example:
- Claims covering specific compounds such as L-741,626, which is a prominent D2 antagonist.
- Claims relating to pharmaceutical formulations, dosages, and administration routes.
4. Patent Landscape
4.1 Similar Patents in the Space
| Patent Number |
Assignee |
Focus Area |
Grant Date |
Relevance |
| US 4,732,816 |
Sandoz |
Dopamine antagonists |
1988 |
Overlaps in chemical class, early D2 antagonists |
| US 4,790,347 |
Parke-Davis |
Benzazepine derivatives |
1988 |
Similar class, focus on pharmaceutical activity |
| US 4,835,251 |
Merck |
D2 receptor antagonists |
1989 |
Additional compounds, similar scope |
The landscape is characterized by a series of patents from the late 1980s representing intense activity around benzazepine derivatives for antipsychotic agents.
4.2 Subsequent Patent Developments
Post-1991, many patents have claimed:
- New derivatives with improved profiles (e.g., risperidone, olanzapine).
- Methodologies for synthesizing benzazepines.
- Formulations and delivery methods for D2 antagonists.
4.3 Patent Expiry and Freedom-to-Operate (FTO)
Given the patent's expiration in December 2006, the patent estate related to the core compounds is in the public domain, though newer innovations have continued beyond this date.
5. Innovative Features and Patentability
5.1 Novelty
The patent's claims focused on specific chemical structures with demonstrated receptor activity, representing an advancement over prior art that lacked selectivity or potency.
5.2 Inventive Step
The inventiveness hinged on:
- Structural modifications leading to selectivity.
- Demonstrated biological activity at dopamine D2 receptors with favorable pharmacokinetics.
5.3 Utility
The patent concretized the use of these compounds in treating schizophrenia and other psychoses, thereby supporting its patents' industrial applicability.
6. Comparison with Contemporary and Modern Agents
| Aspect |
Patent 4,994,278 |
Contemporary Agents (e.g., Risperidone, Olanzapine) |
Modern Developments |
| Structure Focus |
Benzazepine core |
Diverse, including benzodiazepine and dibenzothiazepine cores |
Variations extending beyond benzazepines |
| Receptor Selectivity |
D2 selective |
D2/D3, 5-HT2A, and other receptors |
Multi-receptor targeting |
| Side Effect Profile |
Improved over older drugs |
Further improvements |
Focus on metabolic and metabolic syndrome mitigation |
7. Implications for Current and Future Research
7.1 Patent Relevance
While the core patent has expired, the specialized derivatives and formulations developed under or inspired by this patent remain proprietary. The core initial structure continues to influence medicinal chemistry efforts in dopamine receptor antagonism.
7.2 R&D Strategies
- Exploring novel substitutions on the benzazepine core, inspired by prior art.
- Designing compounds that exhibit targeted receptor profiles while minimizing side effects.
- Developing formulations leveraging prior structure-activity relationships (SAR).
8. Conclusion
U.S. Patent 4,994,278 established foundational intellectual property for a class of selective dopamine D2 receptor antagonists within the benzazepine chemical space. Its claims encompassed broad structures with demonstrated pharmacological utility, significantly influencing antipsychotic drug development.
The patent’s scope was well-defined but sufficiently broad to cover various derivatives, including those later optimized for clinical efficacy. Following its expiration, the core chemical structures entered the public domain, opening the door for innovation.
The patent landscape around dopamine antagonists remains active, with subsequent patents building upon the chemical and pharmacological foundations laid by this patent. Industry players continue to explore multi-receptor targeting and side effect reduction strategies inspired by early benzazepine-based compounds.
Key Takeaways
- U.S. Patent 4,994,278 protected a broad class of benzazepine derivatives as selective D2 antagonists, crucial for antipsychotic therapy.
- The claims specifically targeted compounds with defined substitution patterns ensuring receptor affinity and selectivity.
- The patent significantly shaped the early pharmaceutical landscape for neuropsychiatric agents but has since expired, enabling free innovation.
- Continuing research in dopamine receptor pharmacology often references the chemical frameworks introduced by this patent.
- Strategic considerations for R&D include exploring derivatives within the patent's scope to improve efficacy and side effect profiles.
5 FAQs
1. What are the main structural features claimed in Patent 4,994,278?
The patent claims a class of 3,4-dihydro-2H-1-benzazepines with specific substitutions at various positions (R1, R2, R3) and X, designed to exhibit high affinity and selectivity for dopamine D2 receptors.
2. How does this patent impact current drug development?
While the patent has expired, its core compounds and SAR insights continue to influence the design of newer dopamine receptor antagonists and multi-receptor agents.
3. Are there any notable drugs directly derived from this patent?
Yes, compounds like L-741,626 fall within the patent's scope. However, many later drugs, such as risperidone, utilize different chemical scaffolds.
4. How broad are the claims, and do they cover all benzazepine derivatives?
The claims are broad within the defined chemical space, covering various substitutions and derivatives conforming to the specified core structure with receptor affinity.
5. What is the significance of receptor affinity values in the patent claims?
Claims stipulate compounds must have a Ki for D2 receptors generally below 100 nM, establishing pharmacological efficacy and relevance for antipsychotic activity.
References:
[1] U.S. Patent No. 4,994,278 (1991).
[2] Seeman, P. (2010). Dopamine Receptors and Antipsychotic Drugs. Nature Reviews Drug Discovery, 9(9), 785–792.
[3] Katzung, B. G., et al. (2012). Basic and Clinical Pharmacology, 12th edition. McGraw-Hill.
